In a review of 14 cases of oncocytic adrenocortical carcinomas, beta-catenin was identified as a useful prognostic marker, and IGF-2 overexpression should not be extrapolated to this variant.
Observational (n=14)
What is the clinicopathological and immunohistochemical profile of oncocytic adrenocortical carcinomas?
Beta-catenin is a useful prognostic marker for oncocytic adrenocortical carcinomas, which have a distinct immunohistochemical profile from conventional subtypes.
ABSTRACT Background: Oncocytic subtypes of adrenocortical carcinomas are rare tumor entities, with relatively better prognosis than the conventional subtype. Owing to its rarity, oncocytic adrenocortical carcinomas (OACCs) have not been studied extensively. The study aims to analyze the clinicopathological and therapy-relevant immunohistochemical profile of OACC. Materials and Methods: A total of 14 cases of OACC were retrieved and reviewed. Relevant clinical, demographic, and histopathological information with respect to various scoring systems was collected. Immunohistochemical evaluation for SF1, beta-catenin, insulin-like growth factor-1 receptor, and ki-67 was performed, and results were evaluated. Results and Conclusion: The age range distribution is diverse and estimation of malignant potential using Lin–Weiss Bisceglia scoring criteria of OACC is of paramount importance. Beta-catenin can be applied as a useful marker for prognostication of OACCs. Insulin growth factor-2 overexpression of conventional adrenocortical carcinomas must not be extrapolated to the oncocytic variant.
Kumari et al. (Thu,) conducted a observational in Oncocytic adrenocortical carcinomas (n=14). Immunohistochemical evaluation (SF1, beta-catenin, IGF-1R, ki-67) was evaluated on Clinicopathological and therapy-relevant immunohistochemical profile. In a review of 14 cases of oncocytic adrenocortical carcinomas, beta-catenin was identified as a useful prognostic marker, and IGF-2 overexpression should not be extrapolated to this variant.